Concepedia

Scott K. Pruitt

SK

Statistics

Publications

67

Citations

8.3K

H-Index

37

Active since

1991

Affiliations

Duke Medical Center(Current)

Duke University

Duke University Hospital

Merck & Co., Inc., Rahway, NJ, USA (United States)

Durham VA Medical Center

Scott K. Pruitt is an author at Duke Medical Center specializing in medicine, immunology, and oncology.

Top concepts

Publications per year

1991–2024

67

Publications

67

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 2.8K citations · Full text

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2019 · 1K citations · Full text

Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

Zhen Su, Jens Dannull, Axel Heiser et al. · PubMed · 2003 · 366 citations

, , +18

THE EFFECT OF SOLUBLE COMPLEMENT RECEPTOR TYPE 1 ON HYPERACUTE REJECTION OF PORCINE XENOGRAFTS

Scott K. Pruitt, Allan D. Kirk, R. Randal Bollinger et al. · Transplantation · 1994 · 262 citations

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

Hyun Cheol Chung, José A. López-Martín, Stephen Chuan-Hao Kao et al. · Journal of Clinical Oncology · 2018 · 206 citations

, , +16

1–5 of 67